中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
THE CHINESE JOURNAL OF CLINICAL PHARMACOLOGY
2014年
10期
904-906
,共3页
晚期结直肠癌%奥沙利铂%卡培他滨%沙利度胺
晚期結直腸癌%奧沙利鉑%卡培他濱%沙利度胺
만기결직장암%오사리박%잡배타빈%사리도알
advanced metastatic colorectal cancer%oxaliplatin%capecitabine%thalidomide
目的：评价沙利度胺联合奥沙利铂（ L -OHP）与卡培他滨（ CAP）（XELOX）化疗方案与单纯 XELOX 方案治疗晚期转移性结直肠癌（amCRC）的疗效及安全性。方法103例晚期转移性结直肠癌患者分为沙利度胺联合 XELOX方案化疗（试验组）46例和单纯用 XELOX 方案化疗（对照组）57例。对照组：静脉滴注L -OHP 130 mg? m-2，持续4 h；口服 CAP 1000 mg? m-2，bid，l ～14 d；试验组：在对照组基础上口服沙利度胺200 mg，qn，1～14 d；21 d 为1周期，化疗3周期后进行疗效评价。结果试验组客观有效率（ORR）为34．8％，显著高于对照组的14．0％（P ＜0．05）；试验组中位疾病进展时间为8．1个月，显著高于对照组6．2个月（P ＜0．05）；2组患者胃肠道反应及血液学毒性差别无统计学意义（P ＞0．05）。结论沙利度胺联合 XELOX 化疗方案可提高晚期转移性结直肠癌的临床疗效，延长患者无病生存时间，且不增加患者不良反应。
目的：評價沙利度胺聯閤奧沙利鉑（ L -OHP）與卡培他濱（ CAP）（XELOX）化療方案與單純 XELOX 方案治療晚期轉移性結直腸癌（amCRC）的療效及安全性。方法103例晚期轉移性結直腸癌患者分為沙利度胺聯閤 XELOX方案化療（試驗組）46例和單純用 XELOX 方案化療（對照組）57例。對照組：靜脈滴註L -OHP 130 mg? m-2，持續4 h；口服 CAP 1000 mg? m-2，bid，l ～14 d；試驗組：在對照組基礎上口服沙利度胺200 mg，qn，1～14 d；21 d 為1週期，化療3週期後進行療效評價。結果試驗組客觀有效率（ORR）為34．8％，顯著高于對照組的14．0％（P ＜0．05）；試驗組中位疾病進展時間為8．1箇月，顯著高于對照組6．2箇月（P ＜0．05）；2組患者胃腸道反應及血液學毒性差彆無統計學意義（P ＞0．05）。結論沙利度胺聯閤 XELOX 化療方案可提高晚期轉移性結直腸癌的臨床療效，延長患者無病生存時間，且不增加患者不良反應。
목적：평개사리도알연합오사리박（ L -OHP）여잡배타빈（ CAP）（XELOX）화료방안여단순 XELOX 방안치료만기전이성결직장암（amCRC）적료효급안전성。방법103례만기전이성결직장암환자분위사리도알연합 XELOX방안화료（시험조）46례화단순용 XELOX 방안화료（대조조）57례。대조조：정맥적주L -OHP 130 mg? m-2，지속4 h；구복 CAP 1000 mg? m-2，bid，l ～14 d；시험조：재대조조기출상구복사리도알200 mg，qn，1～14 d；21 d 위1주기，화료3주기후진행료효평개。결과시험조객관유효솔（ORR）위34．8％，현저고우대조조적14．0％（P ＜0．05）；시험조중위질병진전시간위8．1개월，현저고우대조조6．2개월（P ＜0．05）；2조환자위장도반응급혈액학독성차별무통계학의의（P ＞0．05）。결론사리도알연합 XELOX 화료방안가제고만기전이성결직장암적림상료효，연장환자무병생존시간，차불증가환자불량반응。
Objective To evaluate clinical efficacy and safety of thalido-mide plus oxaliplatin ( L -OHP) and capecitabine ( CAP) regimen (XELOX) and single XELOX chemotherapy regimen in the treatment of advanced metastatic colorectal cancer ( amCRC ) . Methods One hundred and three subjects with amCRC were recruited and randomly divided into the XELOX (control group, n =57) and XELOX plus tha-lidomide(treatment group, n =46) group.Control group: L -OHP 130 mg? m-2 through intravenous infusion, lasting for 4 h, CAP 1000 mg? m-2 , bid, po, l to 14 days. Treatment group: L - OHP 130 mg? m-2 through intravenous infusion , lasting for 4 h, CAP 1000 mg? m-2 , bid, po, l to 14 days, as well as thalidomide 200 mg, qn, po, 1 to 14 days.21 days as a cycle.Results The objective response rate (ORR) in treatment group was 34.8%, significantly higher than that of control group (14.0%) (P <0.05); the median time to progression in the treatment group was 8.1 months, much longer than that in the control group (6.2 months) (P <0.05).No statistical differences of gastrointesti -nal reactions and hematologic toxicity were found between the two groups (P >0.05 ) .Conclusion Thalidomide plus XELOX chemotherapy regimen can significantly increase the clinical efficacy on patients with amCRC without increasing adverse reactions .
